Greywolf Therapeutics
@GreywolfHQ
Followers
3
Following
0
Media
5
Statuses
5
We are advancing novel antigen modulation technology that controls T cells to guide the immune system.
Milton
Joined October 2017
We are proud to announce our advancement of GRWD5769 into the clinic as this reflects a critical first step in our evaluation of this first-in-class ERAP1 inhibitor.
0
0
2
Greywolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
0
0
1
Greywolf has developed and is advancing a unique immune-oncology therapeutic strategy utilizing a proprietary antigen modulation strategy to reveal novel and potent cancer antigens on the surface of tumour cells.
0
0
1
Greywolf Therapeutics closes oversubscribed $49 Million Series B financing to advance first-of-its-kind neoantigen creation approaches.
0
0
0
Greywolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab)
0
0
0